Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | Director · Chief Scientific Officer | March 02, 2023 | March 06, 2023 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | June 09, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NGM BIOPHARMACEUTICALS INC
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 972,893 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Grant · Acquired 64,000 · Balance 972,893 F1: Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2033-03-01 | Direct | 192,000 |
Reported balance
After 2023-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-02 · Grant · Acquired 192,000 · Balance 192,000 F2: The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2033-03-01 | Direct | 175,000 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Grant · Acquired 175,000 · Balance 175,000 F3: 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2: The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F3: 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.
Tenaya Therapeutics, Inc.
Report date June 09, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2033-06-08 | Direct | 29,532 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 29,532 · Balance 29,532 F1: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 12, 2023 20:10 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036506 · doc4.xml · derivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 17:05 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-23-016384 · doc4.xml · derivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 17:05 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 192,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-23-016384 · doc4.xml · derivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2033-03-01 F2 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 17:05 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantCommon Stock | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016384 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,893 F1 · shares: Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 85,082 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-23-003702 · doc4.xml · derivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,082 shares Expires 2023-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise occurred because the option was expiring, and shares were sold to pay the exercise price and related tax obligations. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 85,082 | $5.15 | $438,308.43 |
DisclosureSEC source: 0001209191-23-003702 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,893 F1 · kind: The exercise occurred because the option was expiring, and shares were sold to pay the exercise price and related tax obligations. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.015 to $5.30. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 85,082 | $1.44 | $122,518.08 |
DisclosureSEC source: 0001209191-23-003702 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise occurred because the option was expiring, and shares were sold to pay the exercise price and related tax obligations. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 20:49 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 39,727 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-22-036523 · doc4.xml · derivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 16:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001209191-22-016205 · doc4.xml · derivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
| December 07, 2021 Filed Dec 7, 2021 21:54 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $18.60 | $279,000.00 |
DisclosureSEC source: 0001209191-21-068466 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.99. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:54 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 69,444 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-21-068466 · doc4.xml · derivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,082 Underlying: Common Stock · 69,444 shares Expires 2023-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:54 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 69,444 | $1.44 | $99,999.36 |
DisclosureSEC source: 0001209191-21-068466 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:54 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $18.21 | $273,150.00 |
DisclosureSEC source: 0001209191-21-068466 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.79 to $18.49. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $19.56 | $293,400.00 |
DisclosureSEC source: 0001209191-21-064853 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.29 to $19.90. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $19.89 | $298,350.00 |
DisclosureSEC source: 0001209191-21-064853 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.66 to $20.24. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $20.14 | $302,100.00 |
DisclosureSEC source: 0001209191-21-060364 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.52. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $20.41 | $306,150.00 |
DisclosureSEC source: 0001209191-21-060364 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.66. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 21:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 3,037 | $26.13 | $79,356.81 |
DisclosureSEC source: 0001209191-21-056083 · doc4.xml · nonDerivative · entry 5 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 929,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.19. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 21:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 11,963 | $25.54 | $305,535.02 |
DisclosureSEC source: 0001209191-21-056083 · doc4.xml · nonDerivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,486 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $25.04 to $26.02. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 170 | $26.98 | $4,586.60 |
DisclosureSEC source: 0001209191-21-056083 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.92 to $27.07. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 10,910 | $26.17 | $285,514.70 |
DisclosureSEC source: 0001209191-21-056083 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944,619 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.77. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 3,920 | $25.59 | $100,312.80 |
DisclosureSEC source: 0001209191-21-056083 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,529 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 18:48 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 15,000 | $23.15 | $347,250.00 |
DisclosureSEC source: 0001209191-21-050981 · doc4.xml · nonDerivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $22.86 to $23.75. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 18:48 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 600 | $25.62 | $15,372.00 |
DisclosureSEC source: 0001209191-21-050981 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.91. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 18:48 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 6,669 | $25.12 | $167,525.28 |
DisclosureSEC source: 0001209191-21-050981 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $24.49 to $25.46. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 18:48 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 7,731 | $23.81 | $184,075.11 |
DisclosureSEC source: 0001209191-21-050981 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981,718 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $23.44 to $24.29. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 16:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 69,444 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-21-038655 · doc4.xml · derivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,444 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 16:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 69,444 | $1.44 | $99,999.36 |
DisclosureSEC source: 0001209191-21-038655 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 16:39 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $27.62 | $690,500.00 |
DisclosureSEC source: 0001209191-21-029913 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $27.12 to $27.90. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 18:56 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $24.65 | $616,250.00 |
DisclosureSEC source: 0001209191-21-026503 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $24.30 to $25.20. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:25 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $31.93 | $0.00 |
DisclosureSEC source: 0001209191-21-021932 · doc4.xml · derivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-03-16 F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 17:19 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $26.66 | $666,500.00 |
DisclosureSEC source: 0001209191-21-016231 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.22 to $27.00. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 16:19 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $28.75 | $718,750.00 |
DisclosureSEC source: 0001209191-21-011253 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $28.528 to $29.31. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 19:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-21-002374 · doc4.xml · derivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2021-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Pursuant to its terms, the option to purchase these shares expires on February 10, 2021, unless earlier exercised. This transaction represents the exercise of the shares under this incentive stock option by the reporting person prior to the expiration date. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 19:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 150,000 | $0.60 | $90,000.00 |
DisclosureSEC source: 0001209191-21-002374 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Pursuant to its terms, the option to purchase these shares expires on February 10, 2021, unless earlier exercised. This transaction represents the exercise of the shares under this incentive stock option by the reporting person prior to the expiration date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 19:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 370 | $30.26 | $11,196.20 |
DisclosureSEC source: 0001209191-21-002374 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 19:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 24,630 | $29.27 | $720,920.10 |
DisclosureSEC source: 0001209191-21-002374 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,375 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $28.945 to $29.56. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 3,145 | $28.89 | $90,859.05 |
DisclosureSEC source: 0001209191-20-063799 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.50. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 10,729 | $28.19 | $302,450.51 |
DisclosureSEC source: 0001209191-20-063799 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $27.79 to $28.78. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 11,126 | $27.59 | $306,966.34 |
DisclosureSEC source: 0001209191-20-063799 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,879 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.76 to $27.74. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 17:10 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $17.70 | $442,500.00 |
DisclosureSEC source: 0001209191-20-056934 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.355 to $17.79. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 17:52 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $17.02 | $425,500.00 |
DisclosureSEC source: 0001209191-20-054708 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.46. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:18 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 7,613 | $18.32 | $139,470.16 |
DisclosureSEC source: 0001209191-20-049387 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.94. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:18 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 17,387 | $17.62 | $306,358.94 |
DisclosureSEC source: 0001209191-20-049387 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,618 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.28 to $17.98. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 16:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 25,000 | $19.02 | $475,500.00 |
DisclosureSEC source: 0001209191-20-046128 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.77 to $19.425. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:36 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 7,263 | $19.20 | $139,449.60 |
DisclosureSEC source: 0001209191-20-040351 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.315. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:36 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 17,737 | $18.79 | $333,278.23 |
DisclosureSEC source: 0001209191-20-040351 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,268 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.105 to $19.095. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 18:31 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 19,400 | $21.79 | $422,726.00 |
DisclosureSEC source: 0001209191-20-037406 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $21.45 to $22.06. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,562 shares purchased through the Issuer's ESPP on November 15, 2019. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 18:31 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 5,600 | $21.15 | $118,440.00 |
DisclosureSEC source: 0001209191-20-037406 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $20.44 to $21.435. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,562 shares purchased through the Issuer's ESPP on November 15, 2019. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $16.47 | $0.00 |
DisclosureSEC source: 0001209191-20-007326 · doc4.xml · derivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.